Betahistine is a pharmaceutical compound primarily used to treat vertigo and balance disorders, such as Ménière’s disease. It works by improving blood flow in the inner ear, which helps reduce the buildup of pressure that causes dizziness and hearing loss. Chemically, betahistine is a structural analog of histamine and acts as a weak histamine H1 receptor agonist and a strong H3 receptor antagonist. The drug was first synthesized and introduced in the 1960s, with initial research focusing on its effects on the vestibular system. Over the decades, betahistine gained acceptance worldwide due to its efficacy in managing symptoms related to inner ear disorders. It is administered orally, typically in tablet form, and is considered safe with relatively mild side effects. Betahistine’s mechanism of action involves vasodilation in the inner ear and modulation of neurotransmitter release, which contributes to its symptom-relieving effects. Research continues into its broader applications, including potential benefits in cognitive disorders linked to vestibular dysfunction. Today, it remains one of the most commonly prescribed treatments for vertigo and balance-related ailments globally.
